Skip to main content
. Author manuscript; available in PMC: 2018 Mar 8.
Published in final edited form as: J Am Chem Soc. 2017 Feb 27;139(9):3446–3455. doi: 10.1021/jacs.6b11273

Figure 8.

Figure 8

Targapremir-210 impedes tumor proliferation in vivo. (A) Live bioluminescent imaging of NOD/SCID mice 3 weeks postimplantation of MDA-MB-231-GFP-Luc cells either pretreated in vitro with Targapremir-210 or miR-210 antagomir (top) or administered with a single injection of Targapremir-210 or miR-210 antagomir 24 h postimplantation (bottom). (B) Resected tumor masses from NOD/SCID mice administered with a single injection of either Targapremir-210 or miR-210 antagomir 24 h post tumor implantation. (C) Real-time qPCR of resected tumor masses demonstrating on-target effects of miR-210 inhibition by Targapremir-210. * Indicates p < 0.05 compared to untreated mice, as determined by a two-tailed Student t test.